Stocktoria
Rani Therapeutics Holdings, Inc. RANI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-07-30
Chart by TradingView
4/9
Piotroski F — financial health
-4.67
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $1.6M | $1.0M | $0 | $0 | $2.7M |
| Operating income | -$38.3M | -$53.3M | -$66.1M | -$63.5M | -$51.6M |
| Net income | -$29.7M | -$30.0M | -$34.0M | -$30.6M | -$8.3M |
| Operating cash flow | -$18.7M | -$35.5M | -$51.2M | -$46.5M | -$32.2M |
| Free cash flow | -$18.8M | -$35.8M | -$52.5M | -$48.1M | -$32.8M |
| Total assets | $58.6M | $36.6M | $57.9M | $108.0M | $124.2M |
| Total liabilities | $17.1M | $33.1M | $32.5M | $34.0M | $2.6M |
| Shareholders' equity | $41.5M | $3.5M | $25.4M | $74.0M | $121.6M |
| Ratios | |||||
| Operating margin | -2346.0% | -5186.2% | — | — | -1899.1% |
| Net margin | -1817.1% | -2920.0% | — | — | -306.6% |
| FCF margin | -1151.4% | -3479.0% | — | — | -1205.4% |
| Return on assets | -50.6% | -81.9% | -58.7% | -28.3% | -6.7% |
| Return on equity | -71.5% | -859.4% | -133.5% | -41.3% | -6.9% |
| Debt / equity | 0.00× | 2.75× | 0.96× | 0.39× | 0.00× |
| Current ratio | 4.21 | 1.50 | 6.36 | 20.96 | 45.30 |
| Revenue growth | 58.9% | — | — | -100.0% | 488.1% |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -4.67 (distress)
- Working capital / assets 0.693
- Retained earnings / assets -2.262
- EBIT / assets -0.654
- Equity / liabilities 2.426
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001856725 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.